Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TAVR for low-risk bicuspid aortic stenosis appears safe, effective

Key clinical point: Early outcomes for low-risk bicuspid TAVR rivaled those of propensity-matched surgical valve replacement patients.

Major finding: There were no deaths, no disabling strokes, and improved hemodynamics 30 days after TAVR for bicuspid aortic stenosis.

Data Source: A prospective, multicenter registry of TAVR patients with bicuspid aortic valves.

Disclosures: Dr. Waksman reported financial relationships with many TAVR device companies. This study had no industry funding.


Waksman R. CRT 2020.